Phase Separation Rewires Chromatin in Breast Cancer

Overview

Journal Nat Cancer

Specialty Oncology

Date 2024 Oct 25

PMID 39455848

Authors

Rosaria Benedetti

Lucia Altucci

Affiliations

Soon will be listed here.

References

Thomas A, Reis-Filho J, Geyer Jr C, Wen H . Rare subtypes of triple negative breast cancer: Current understanding and future directions. NPJ Breast Cancer. 2023; 9(1):55. PMC: 10290136. DOI: 10.1038/s41523-023-00554-x. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E . Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. Nat Cancer. 2024; 5(11):1713-1736. PMC: 11584403. DOI: 10.1038/s43018-024-00773-6. View

Nogues L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M . G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis. EBioMedicine. 2016; 13:132-145. PMC: 5264252. DOI: 10.1016/j.ebiom.2016.09.030. View

Bergman J, Woan K, Perez-Villarroel P, Villagra A, Sotomayor E, Kozikowski A . Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012; 55(22):9891-9. PMC: 3562128. DOI: 10.1021/jm301098e. View

Kantidze O, Razin S . Weak interactions in higher-order chromatin organization. Nucleic Acids Res. 2020; 48(9):4614-4626. PMC: 7229822. DOI: 10.1093/nar/gkaa261. View

Mehta S, Zhang J . Liquid-liquid phase separation drives cellular function and dysfunction in cancer. Nat Rev Cancer. 2022; 22(4):239-252. PMC: 10036213. DOI: 10.1038/s41568-022-00444-7. View

Ahn J, Davis E, Daugird T, Zhao S, Quiroga I, Uryu H . Phase separation drives aberrant chromatin looping and cancer development. Nature. 2021; 595(7868):591-595. PMC: 8647409. DOI: 10.1038/s41586-021-03662-5. View

Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H . Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer. 2022; 4(2):257-275. PMC: 9992270. DOI: 10.1038/s43018-022-00489-5. View

10.

Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C . HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer. Cancer Res. 2020; 80(17):3649-3662. PMC: 7484424. DOI: 10.1158/0008-5472.CAN-19-3738. View

11.

Hey J, Llamazares Prada M, Plass C . HDAC6 score: to treat or not to treat?. Nat Cancer. 2022; 4(2):156-158. DOI: 10.1038/s43018-022-00494-8. View

12.

Medard G, Sheltzer J . Ricolinostat is not a highly selective HDAC6 inhibitor. Nat Cancer. 2023; 4(6):807-808. DOI: 10.1038/s43018-023-00582-3. View

13.

Silva J, Yu J, Kalinsky K . Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor. Nat Cancer. 2023; 4(6):809-811. DOI: 10.1038/s43018-023-00583-2. View

14.

Sadar M . Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor. Expert Opin Drug Discov. 2020; 15(5):551-560. PMC: 8693730. DOI: 10.1080/17460441.2020.1732920. View

15.

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T . Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021; 6(1):201. PMC: 8165101. DOI: 10.1038/s41392-021-00572-w. View